Replies to post #110259 on Biotech Values

[vinmantoo]

gradstudent,

It depends on the price being offered, and for the record, I wouldn't be in favor of an ONXX deal unless it was for a very high price. As to why people become hot on it, well it is an immediate guaranteed return vs the prospect for a greater potential return. The old bird in the hand vs the two in the bush argument.

[microcapfun]

>>As for Onyx, it seems like an even worse proposition. If they're able to get a second drug on the market, then I think they reach that sweet spot of really making some money.<<

One thing to keep in mind is that Carfilzomib has to be marketed to a quite different set of doctors compared to Nexavar - hematologists instead of oncologists, hepatologists, etc. Also Onyx plans to do its own marketing for Carfilzomib in Europe, which means ramping up from scratch there. My point is that there may not be much synergy associated with marketing these two very different drugs.

micro

[vinmantoo]

Gradstudent,

It depends on the price a buyout is offered. $50 wouldn't be good, $100 would be great.